Literature DB >> 19901913

Intrarenal expression of microRNAs in patients with IgA nephropathy.

Gang Wang1, Bonnie C-H Kwan, Fernand M-M Lai, Paul C-L Choi, Kai-Ming Chow, Philip K-T Li, Cheuk-Chun Szeto.   

Abstract

MicroRNAs (miRNAs) are noncoding, single-stranded RNA molecules that have important roles in a number of physiological and pathological processes. Previous studies have proved that miRNAs targeting ZEB1 and ZEB2 may repress epithelial-to-mesenchymal transition. In this work, we studied the intrarenal expression of miR-200 family, miR-205 and miR-192 in patients with immunoglobulin A (IgA) nephropathy. We studied 43 patients with biopsy-proven IgA nephropathy (IgA group). The intrarenal expression of miRNAs was quantified and compared with that of 15 patients with noninflammatory glomerulosclerosis (GS group) and 20 patients with nephrectomy for kidney cancer as controls (CTL group). The level of intrarenal miR-200c was downregulated, whereas the levels of intrarenal miR-141, miR-205 and miR-192 were upregulated in IgA but not GS group. Proteinuria significantly correlated with the intrarenal expression of miR-200c (r=-0.324, P=0.011) and glomerular filtration rate (GFR) significantly correlated with the intrarenal expression of miR-205 (r=-0.280, P=0.030). The degree of tubulointerstitial scarring correlated with miR-205 expression (r=0.389, P=0.021), whereas glomerulosclerosis correlated with miR-192 expression (r=-0.311, P=0.045). The rate of GFR decline significantly correlated with the intrarenal expression of miR-192 (r=0.373, P=0.015). The intrarenal expression of E-cadherin significantly correlated with the intrarenal expression of miR-200c (r=0.392, P=0.002). The results show that intrarenal expression of miR-200c, miR-141, miR-205 and miR-192 was diversely regulated and correlated with disease severity and progression in patients with IgA nephropathy. These miRNA species may be important in the pathogenesis and progression of IgA nephropathy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19901913     DOI: 10.1038/labinvest.2009.118

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  51 in total

Review 1.  MicroRNAs in kidney development: lessons from the frog.

Authors:  Oliver Wessely; Raman Agrawal; Uyen Tran
Journal:  RNA Biol       Date:  2010-05-02       Impact factor: 4.652

Review 2.  MicroRNAs in renal development.

Authors:  Jacqueline Ho; Jordan A Kreidberg
Journal:  Pediatr Nephrol       Date:  2012-06-02       Impact factor: 3.714

3.  The long and short of microRNAs in the kidney.

Authors:  Jacqueline Ho; Jordan A Kreidberg
Journal:  J Am Soc Nephrol       Date:  2012-02-02       Impact factor: 10.121

Review 4.  MicroRNAs as mediators and therapeutic targets in chronic kidney disease.

Authors:  Johan M Lorenzen; Hermann Haller; Thomas Thum
Journal:  Nat Rev Nephrol       Date:  2011-03-22       Impact factor: 28.314

Review 5.  Translational study of microRNAs and its application in kidney disease and hypertension research.

Authors:  Alison J Kriegel; Domagoj Mladinov; Mingyu Liang
Journal:  Clin Sci (Lond)       Date:  2012-05-01       Impact factor: 6.124

Review 6.  microRNAs in kidneys: biogenesis, regulation, and pathophysiological roles.

Authors:  Kirti Bhatt; Qing-Sheng Mi; Zheng Dong
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-12

Review 7.  Genomic biomarkers for chronic kidney disease.

Authors:  Wenjun Ju; Shahaan Smith; Matthias Kretzler
Journal:  Transl Res       Date:  2012-02-09       Impact factor: 7.012

Review 8.  MicroRNAs and the glomerulus.

Authors:  Mitsuo Kato; Jung Tak Park; Rama Natarajan
Journal:  Exp Cell Res       Date:  2012-03-05       Impact factor: 3.905

9.  Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy.

Authors:  Grazia Serino; Fabio Sallustio; Sharon N Cox; Francesco Pesce; Francesco P Schena
Journal:  J Am Soc Nephrol       Date:  2012-02-23       Impact factor: 10.121

10.  E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta.

Authors:  Bo Wang; Michal Herman-Edelstein; Philip Koh; Wendy Burns; Karin Jandeleit-Dahm; Anna Watson; Moin Saleem; Gregory J Goodall; Stephen M Twigg; Mark E Cooper; Phillip Kantharidis
Journal:  Diabetes       Date:  2010-04-14       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.